295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
RIVM identifies three major challenges for public health and healthcare in period to 2050 The Dutch public health and healthcare will face three crucial challenges in the period to 2050. This is according to RIVM’s preview of the Dutch Public Health Foresight Study 2024.
Predicting who will experience symptoms after Lyme disease remains challenging Each year, approximately 27,000 people are diagnosed with Lyme disease. For most, the symptoms disappear after treatment with antibiotics. Unfortunately, 25% of those treated have chronic symptoms, such as fatigue, concentration disorders or pain.
Number of Lyme disease diagnoses remains high In 2021, the number of Lyme disease diagnoses with a red ring or rash– known as an erythema migrans, or EM – remained as high as in the previous survey in 2017. GPs diagnosed 25,600 patients with a red ring or rash caused by the Lyme bacteria.
Breast implants can cause health problems even five years or more after placement Over the past 5 years, the Dutch reporting and expertise centre for adverse effects of medical implants (MEBI) has received 977 reports of health problems related to breast implants. An analysis by RIVM has shown that 39% of the reported health problems started 5 or more years after the implant’s placement.
No indication that investigated mesh implants used to treat pelvic organ prolapse are unsafe RIVM has conducted a laboratory study into six mesh implants from different manufacturers used in the Netherlands in 2018. The study revealed no indication that these products are unsafe for patients.
Reducing greenhouse gas emissions via procurement partnerships By optimising collaboration when purchasing products and services, the government can reduce greenhouse gas emissions. This was the conclusion of a study by the National Institute for Public Health and Environmental Protection (RIVM) into so-called 'buyer groups'.
Hypersensitivity reactions to fillers may occur after COVID-19 vaccination People may experience hypersensitivity reactions to fillers following a COVID-19 vaccination.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Antibiotic use and antimicrobial resistance remain stable Antibiotic resistance in the Netherlands remained stable in 2021 compared with the five previous years. This is evident from the 2022 annual NethMap/MARAN report.